CompletedPhase 2

Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's Disease

Lead sponsor

National Center for Research Resources (NCRR)

Assets

Donepezil / estrogen / Progesterone

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criteria

•Age 45-85•Female

Primary endpoint

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Nih2R56AG021476

Org study IDIA0023

NCT IDNCT00006399

Timeline

Milestones

Study start1999-09 (month precision)

Study first posted2000-08-21estimated

Primary completion2004-03actual (month precision)

Study completion2004-03actual (month precision)

Last update posted2009-01-15estimated

Assets

Drug assets

Donepezil estrogen Progesterone

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age45 Years

Maximum age85 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•Normal volunteers and women with mild Alzheimer's disease:

•Non-smoker

•No use of Hormone Replacement Therapy for at least one year

•No menses for at least one year

•Normal mammogram within the last year

•minimum age is 45 for patients with Alzheimer's disease; 50 for normal volunteers

•Maximum age is 85 for patients with Alzheimer's disease; there is no maximum age for normal volunteers

Exclusion criteria

•Women who are currently taking estrogen therapy.

•Women who are smokers.

•Women who have had breast cancer.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.